Edward Arias
Medical · Sacramento, CANPI 1922018993
Payments from drug & device makers
Across 218 payments — averaging $21.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$667
- Neurocrine Biosciences, Inc.$634
- AstraZeneca$335
- Biohaven Pharmaceutical Holding Company Ltd.$241
- AbbVie$234
- Teva Pharmaceuticals USA, Inc.$209
- plus $2K from 33 others
What the payments were for
- Food & beverage$4,709100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Flexitouch Plus$146
- Entre Plus$146
- Epidiolex$122
- LOKELMA$108
How this compares
$4,709 in reported general payments places this provider in the 85th percentile of 2,087 medical providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 101 | $49,696 |
| JardianceEmpagliflozin | 63 | $45,213 |
| Xtampza ErOxycodone Myristate | 27 | $35,782 |
| OzempicSemaglutide | 31 | $33,408 |
| XareltoRivaroxaban | 33 | $26,220 |
| JanuviaSitagliptin Phosphate | 34 | $21,438 |
| TrulicityDulaglutide | 18 | $18,685 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 622 | $16,317 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $13,486 |
| Breo ElliptaFluticasone/Vilanterol | 28 | $11,353 |
| MyrbetriqMirabegron | 21 | $10,449 |
| LyricaPregabalin | 12 | $10,359 |
| EntrestoSacubitril/Valsartan | 14 | $9,292 |
| Incruse ElliptaUmeclidinium Bromide | 22 | $7,256 |
| BelsomraSuvorexant | 16 | $6,411 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Lyrica | $22 | $60,055113 claims |
| Boehringer IngelheimJardiance | $127 | $45,21363 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $88 | $35,78227 claims |
| Novo NordiskOzempic | $198 | $33,40831 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $28 | $32,09568 claims |
| MerckJanuvia, Belsomra | $64 | $27,84950 claims |
| Lilly USA, LLCTrulicity | $170 | $18,68518 claims |
| NovartisEntresto | $99 | $9,29214 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $16 | $5,18011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,087 medical providers in California.
Other medical in Sacramento
- Kathryn CunninghamSacramento$91K
- Jacinda ChanSacramento$31K
- Joshua OppermanSacramento$26K
- Nicola LowreyOrange$655K
- Justin LoveLoma Linda$553K
- David DoriguzziLancaster$514K
- Alison GracomIrvine$467K
- Jeffrey BonnaudLos Angeles$314K
- Ana TorresLaguna Beach$229K
- Heather ParlettRedlands$168K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.